» Articles » PMID: 35130761

The Current State of Fat Grafting in the Hand: A Systematic Review for Hand Diseases

Overview
Journal Hand (N Y)
Publisher Sage Publications
Date 2022 Feb 8
PMID 35130761
Authors
Affiliations
Soon will be listed here.
Abstract

Autologous fat grafting (AFG) has traditionally been used for facial rejuvenation and soft tissue augmentation, but in recent years, its use has expanded to treat diseases of the hand. Autologous fat grafting is ideal for use in the hand because it is minimally invasive, can restore volume, and has regenerative capabilities. This review summarizes the emerging evidence regarding the safety and efficacy of AFG to the hand in several conditions, including systemic sclerosis, Dupuytren disease, osteoarthritis, burns, and traumatic fingertip injuries. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant literature search on the use of AFG in hand pathologies was performed on October 8, 2020, in Ovid MEDLINE, Elsevier Embase, Clarivate Web of Science, and Wiley Cochrane Central Register of Controlled Trials. The retrieved hits were screened and reviewed by 2 independent reviewers and a third reviewer adjudicated when required. Reviewers identified 919 unique hits. Screening of the abstracts identified 22 manuscripts which described the use of AFG to treat an identified hand condition. Studies suggest AFG in the hands is a safe, noninvasive option for the management of systemic sclerosis, Dupuytren contracture, osteoarthritis, burns, and traumatic fingertip injuries. While AFG is a promising therapeutic option for autoimmune, inflammatory, and fibrotic disease manifestations in the hand, further studies are warranted to understand its efficacy and to establish more robust clinical guidelines. Studies to date show the regenerative, immunomodulatory, and volume-filling properties of AFG that facilitate wound healing and restoration of hand function with limited complications.

Citing Articles

Limited fasciectomy with versus without autologous adipose tissue grafting for treatment of Dupuytren's contracture (REMEDY): study protocol for a multicentre randomised controlled trial.

Sawaya E, Sommier B, Alet J, Piechaud P, Lecoq F Trials. 2024; 25(1):577.

PMID: 39223657 PMC: 11367824. DOI: 10.1186/s13063-024-08410-4.

References
1.
Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L . Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol. 2017; 53(3):306-336. DOI: 10.1007/s12016-017-8625-4. View

2.
Conde-Green A, Wu I, Graham I, Chae J, Drachenberg C, Singh D . Comparison of 3 techniques of fat grafting and cell-supplemented lipotransfer in athymic rats: a pilot study. Aesthet Surg J. 2013; 33(5):713-21. DOI: 10.1177/1090820X13487371. View

3.
Pignatti M, Spinella A, Cocchiara E, Boscaini G, Lusetti I, Citriniti G . Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study. Aesthetic Plast Surg. 2020; 44(5):1820-1832. DOI: 10.1007/s00266-020-01848-2. View

4.
Pearson D, Werth V, Pappas-Taffer L . Systemic sclerosis: Current concepts of skin and systemic manifestations. Clin Dermatol. 2018; 36(4):459-474. DOI: 10.1016/j.clindermatol.2018.04.004. View

5.
Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove C, Bovenkerk J . Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004; 109(10):1292-8. DOI: 10.1161/01.CIR.0000121425.42966.F1. View